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Abstract 
Background: Adverse drug events (ADEs), harmful unintended consequences of medication use, are a leading cause 
of hospital admissions, yet are rarely documented in a structured format between care providers. We describe pilot-
testing structured ADE documentation fields prior to integration into an electronic medical record (EMR).
Methods: We completed a qualitative study at two Canadian hospitals. Using data derived from a systematic review 
of the literature, we developed screen mock-ups for an ADE reporting platform, iteratively revised in participatory 
workshops with diverse end-user groups. We designed a paper-based form reflecting the data elements contained 
in the mock-ups. We distributed them to a convenience sample of clinical pharmacists, and completed ethnographic 
workplace observations while the forms were used. We reviewed completed forms, collected feedback from pharma-
cists using semi-structured interviews, and coded the data in NVivo for themes related to the ADE form.
Results: We completed 25 h of clinical observations, and 24 ADEs were documented. Pharmacists perceived the 
form as simple and clear, with sufficient detail to capture ADEs. They identified fields for omission, and others requir-
ing more detail. Pharmacists encountered barriers to documenting ADEs including uncertainty about what consti-
tuted a reportable ADE, inability to complete patient follow-up, the need for inter-professional communication to rule 
out alternative diagnoses, and concern about creating a permanent record.
Conclusion: Paper-based pilot-testing allowed planning for important modifications in an ADE documentation form 
prior to implementation in an EMR. While paper-based piloting is rarely reported prior to EMR implementations, it can 
inform design and enhance functionality. Piloting with other groups of care providers and in different healthcare set-
tings will likely lead to further revisions prior to broader implementations.
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Background
Adverse drug events (ADEs) are harmful and unintended 
consequences of medications that account for 1.8 mil-
lion emergency department visits in Canada each year, 
and are a leading cause of unplanned admissions (Hohl 
et al. 2001; Zed et al. 2008; Budnitz et al. 2011). Despite 
the significant burden that ADEs pose on patients and 
the healthcare system, they are often not documented by 
clinicians, nor effectively communicated between health 
professionals or across healthcare settings (Hohl et  al. 
2005, 2010), contributing to unintentional re-exposures 
of culprit drugs and repeat ADEs (Zhang et al. 2007). Van 
der Linden et al. (2006) estimate that 27 % of medications 
withdrawn during hospitalization due to an ADE are re-
prescribed within only 6  months, indicating an urgent 
need to develop electronic systems that can help clinical 
care providers prevent repeat unintentional exposures 
to harmful drugs. In a recent systematic review, under-
reporting of ADEs by healthcare providers was identi-
fied as the main reasons why the effectiveness of current 
electronic systems to prevent unintentional re-expo-
sures is limited (Van der Linden et  al. 2013). Improved, 
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structured electronic documentation of ADEs may facili-
tate the creation of patient-specific report that can be 
used to generate medication-level or medication class-
level alerts to prevent unintentional re-exposures (Van 
der Linden et al. 2015).
While many electronic medical records (EMRs) pro-
vide dedicated space allowing care providers to record 
ADEs, most are focused on allergy information and do 
not provide the option for structured reporting (Van der 
Linden et al. 2013). A systematic review of ADE reporting 
systems that are external to EMRs (e.g., Health Canada’s 
Medwatch program) found wide variation in the variety 
and type of ADE data collected (submitted). None of the 
systems reported pilot-testing electronic fields prior to 
their implementation to ensure user-friendliness, suc-
cinctness, relevance and correct interpretation of fields 
by care providers. In participatory workshops completed 
by our group reflecting the views of over 120 care provid-
ers in varied clinical settings, the length of ADE reporting 
forms, the time required to complete them, duplication 
of information requested, and lack of relevance to clini-
cal care were barriers to ADE documentation (submitted 
and unpublished data). Creating structured, succinct and 
clear ADE data input fields in electronic record systems 
that can be leveraged to create patient-specific safety 
alerts to avoid unintentional re-prescribing was per-
ceived as an incentive to report.
The design of electronic information systems in health-
care is complex, as systems must be user-friendly, meet 
the needs of multiple end-user groups, require approval 
from a broad range of stakeholders, and be adaptable to 
multiple environments (Kushniruk 2002). New systems 
implemented without pilot-testing and refining often 
fall short of anticipated goals due to design failures, or 
systems’ architecture constraints that could have been 
identified and addressed prior to their final build. This 
is particularly evident in healthcare where the rapidly 
changing user needs, incomplete information and shift-
ing goals can derail even the most meticulously planned 
system implementation (Kushniruk 2002). Pilot studies 
provide an opportunity to evaluate new concepts at inter-
mediate stages of design (Tejilingen et al. 2001). However, 
piloting electronic data forms is time-consuming and 
costly, as reprogramming is required to introduce refine-
ments. Instead, pilot-testing paper-based forms may yield 
more advanced designs at lower cost and save the time 
and costs required to reprogram interfaces (Grady 2000). 
Paper-based, iterative design has been widely adopted by 
software developers, yet few examples of this approach 
in healthcare systems design exist (Anderson et al. 2001; 
Girsedale et al. 1997). Our objective is to describe paper-
based piloting of a new electronic ADE documentation 
platform that aims to enhance communication between 




This qualitative study was part of a larger research pro-
gram, which has as its goal the design and implementa-
tion of an electronic ADE reporting system within an 
EMR at thirteen hospitals (Peddie et al. 2016). This study 
was conducted in the emergency departments and hos-
pital wards of Vancouver General Hospital (VGH), a ter-
tiary care referral, and Lions Gate Hospital (LGH), an 
urban community hospital in British Columbia, Canada, 
between June and August, 2015.
Compliance with ethical standards
The University of British Columbia Clinical Research 
Ethics Board approved the study protocol (H13-02316-
009). We obtained verbal informed consent from all 
participants. This study was funded by the Canadian 
Institutes of Health Research (Grant No. 2935460). None 
of the authors have any conflicts of interest to declare.
Study participants
We enrolled a convenience sample of key informants, all 
of whom were clinical pharmacists working in settings 
with a high ADE prevalence. We recruited participants 
by sending email invitations to all clinical pharmacists 
working at both institutions through the Department of 
Pharmaceutical Sciences, and encouraged volunteers to 
recruit colleagues by word-of-mouth. The only inclusion 
criterion was that participants actively practice clinical 
pharmacy at a participating hospital.
Design of the paper‑based ADE form
We previously identified a minimum required dataset 
for ADE reporting by conducting a systematic review of 
the literature (submitted), and eight participatory work-
shops with over 120 physician and pharmacist end users 
working in inpatient and outpatient settings across our 
healthcare region. The participants identified which data 
fields were relevant, and proposed a sequence in which 
fields should be presented to end-users to enhance func-
tionality. We used this information to draft a paper-
based version of the electronic reporting form (Fig.  1), 
and organized individual ADE fields into boxes labeled 
A to I to help with the progression of the form (Table 1). 
The electronic version will use auto-populating fields 
that contain medication dispensing information from 
drug plan data which we could not represent in the 
paper-based form. 
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Adverse Drug Event Reporting Form
A. Select Suspect Drugs**
**In the electronic version, this section will 
self-populate a checklist with the current list of 
drugs from Pharmanet, BPMH and active 
inpatient medications. You will also have an 
option of manually entering the medication. 
After you select the culprit medications from 
this list, in the electronic version they would 
populate the LIGHT GREY fields in this form. In 
the paper form please fill them out manually.
For the purpose of this form, please list names 
of suspect drugs only
B1. Suspect Drug 1














C. What type of Adverse Drug Event do 
you suspect?











Describe the drug interaction:
E. Treatment recommended or administered 












D. Are there symptoms, diagnoses, or 
laboratory tests that you suspect are a 
manifestation of the Adverse Drug Event?
Symptom caused or exacerbated by the Adverse Drug 
Event
Diagnosis caused or exacerbated by the Adverse Drug 
Event
Relevant laboratory data (include dates)
Additional comments
B2. Suspect Drug 2




















Improved without complete resolution
No change
Indicate your level of certainty that the 


















F. Add new medications
Specify new medication 1 Dose Route Frequency Start date
Other treatments/ Additional comments
Specify new medication 2 Dose Route Frequency Start date
Other treatments/ Additional comments 
H. Report submission – note this is for 
STUDY PURPOSES ONLY, no actual report 
will be submitted based on this format at this 
time
Report is incomplete (will remain in inpatient 
system only)
Report is complete (will be recorded by 
Health Canada)
Communicate to outpatient provided in 
Pharmanet
I. Follow-up items
Fig. 1 Paper-version of the electronic ADE reporting form
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Data collection
We used lightweight ethnography, a social science 
approach allowing investigators to collect specific and 
relevant information efficiently while accepting the 
impossibility of a complete understanding of a work set-
ting (Randall et  al. 2007). Lightweight ethnography can 
provide guidelines for technology design as it is neither 
time nor resource intensive, and is well suited for pilot 
studies. One research assistant (AC) shadowed clini-
cal pharmacists during 2–4  h data collection shifts. At 
the beginning of each observation shift, the research 
assistant presented pharmacists with the ADE form and 
explained the form functionality, as well as the scope of 
ADEs that it is aimed to capture. Pharmacists were asked 
to complete the form when an ADE was encountered. 
In addition to collecting ethnographic information, the 
research assistant recorded how long it took users to 
complete the form, from the moment they started filling 
it out to when it was ready to be submitted. The research 
assistant also recorded the types of information sources 
accessed and the number of internal and external inter-
ruptions to pharmacists’ work while completing the 
form. Internal interruptions were defined as instances 
where the user had to access another information source 
in order to complete the form. External interruptions 
were defined as instances where another person inter-
rupted the user completing the ADE form. The research 
assistant recorded pharmacists’ comments and impres-
sions during work, and subsequently completed semi-
structured interviews with pharmacists about the 
diagnostic process, users’ perceptions of individual fields 
and the form as a whole, and challenges in documenting 
ADEs. We collected all completed ADE reporting forms 
after each shift.
Data analysis
We calculated the proportion of completed data fields 
for individual ADE reporting forms by taking the num-
ber of data fields completed by the user and dividing this 
number by the twenty-seven data collection fields con-
tained on the ADE form. An individual data collection 
field was defined as one unique question-response pair. A 
data field was marked as filled, if the user provided either 
a written response or checked off a tick-box. The form 
was divided into boxes labeled A to I. Boxes B, “Suspect 
drug”, and F, “Add new medication”, contain duplicate 
spaces to accommodate users entering more than one 
drug at a time. If only one culprit drug was suspected, 
the duplicate space was left out of the average data field 
completion rate calculations. If two culprit drugs were 
suspected, the duplicate space was included in calcula-
tions. To calculate the average data field completion rates 
across all users, we averaged the individual completion 
rates from all the collected forms. The average and stand-
ard deviation for the number of interruptions and time to 
complete the form were used to calculate the 95 % con-
fidence intervals. We transcribed field notes and coded 
data using NVivo 10, a qualitative data analysis software 
that can be used to interrogate and analyze unstructured 
qualitative data. We combined inductive reasoning (mov-
ing from particular to general) and constant comparison 
(generalizing concepts and categories) to code the data 
Table 1 Data collection fields used in the paper version of the ADE reporting form
Concept Data field Field description
Name and dose of the culprit drug(s) A. Select suspect drug(s) Enter a list of suspected drugs
B. Suspect drug(s) Enter the name(s), dose, route of administration, 
frequency, indication for, date of last dispense, and 
other relevant information about the suspect drug
Effect(s) of the ADE on the patient C. What type of ADE do you suspect? Select the type of ADE that occurred, if it was a drug-
drug interaction, describe it in more detail
D. Are there symptoms, diagnoses, or laboratory tests 
that you suspect are an ADE manifestation?
Describe the symptoms and/or diagnosis caused or 
exacerbated by the ADE. Include relevant laboratory 
data and additional comments
Treatment received E. Treatment recommended or administered Describe the treatment for the ADE
F. Add new medications List any newly recommended medications
Outcome G. Causality and outcome Describe what happened to the patient’s symptoms 
after treatment, the outcome of the ADE, and indi-
cate the level of certainty that the event was caused 
by the suspect drug. List additional comments
H. Report submission Indicate whether the report should remain in the 
inpatient record, be submitted to Health Canada or 
communicated to the drug plan
I. Follow-up items List additional comments
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for themes related to the ADE form, challenges in diag-
nosing and reporting ADEs, and workflow.
Results
ADE reporting
We observed six clinical pharmacists for 25 h across 11 
data collection shifts at VGH and LGH. During this time, 
pharmacists completed 24 ADE forms. The clinical phar-
macists perceived the paper-based ADE form as an effi-
cient, user-friendly, and intuitive way to record ADEs. 
Users preferred the form on a single page, and preferred 
checkboxes over drop-down menus and free text. They 
also felt that some data entry fields could be omitted 
(Table  2). For example, pharmacists indicated that sec-
tion B, “Suspect Drug”, should be better at capturing the 
order in which medications were prescribed. Pharmacists 
also felt that subsection of “Suspect Drug”—“date of last 
dispense” lacked utility and could be removed. Users felt 
that instructions for some fields needed further clarifica-
tion or simplification. For example, section F, “Add new 
medications”, required clarification. Pharmacists were 
unsure about whether to list medications used to treat 
an ADE, a drug that was prescribed to replace a culprit 
medication that was discontinued, or both. They also 
thought that section H, “Report submission” was confus-
ing, as it contained multiple reporting options (Table 2).
During piloting, we observed that pharmacists inter-
preted the word “reporting” in our form to imply that its 
purpose was to generate an ADE report for Health Can-
ada, something they felt was outside of the scope of clini-
cal care provision.
Barriers to reporting
Pharmacists were most likely to report more severe or 
rare ADEs, and adverse drug reactions were seen as 
the most “reportable” events. Pharmacists were gener-
ally hesitant to report ADEs when they were concerned 
about creating a permanent record without the ability to 
update, modify or delete it (e.g., if an alternative diagno-
sis became obvious at a later point in time), even though 
we emphasized that this would be possible in an elec-
tronic version. Pharmacists also thought that some ADE 
diagnosis might become irrelevant with time (e.g., a per-
son with orthostatic hypotension caused by a high drug 
dose, who becomes more hypertensive with time and 
requires higher doses of said hypertensive medication). 
This indicated the need to for pharmacists to be able to 
re-access and modify electronic reports. Although phar-
macists were familiar with the scope of ADEs intended to 
be captured by this form, some ADEs were challenging 
to recognize and diagnose. In these instances pharma-
cists remained uncertain about which events warranted 
Table 2 Comments and proposed resolutions
NA not applicable, MD physician
Data field Comments Proposed solution
A. Select suspect drug(s) None NA
B. Suspect drug(s) “Date of last dispense” is irrelevant
Difficult to capture order of prescribing
Difficult to enter complex dosage regimes
Remove the “date of last dispense” field
Increase the amount of free-text entry
Remove one data entry box for drugs (to 
autopopulate in electronic form)
C. What type of ADE do you suspect? Checkboxes preferred over drop-down menus
Provide the option to describe “other”
Use check boxes instead of drop-down menus
Modify the free-text option
D. Are there symptoms, or laboratory 
tests that you suspect are an ADE 
manifestation?
Provide space to list vital signs Add option to add vitals in the “laboratory data” 
section
E. Treatment recommended  
or administered
Need to be able to input start and stop time of the 
changes
Add a “start” and “stop” date data input
F. Add new medications Name of field is confusing
Unsure about which medications to list
Change the name of the box to clarify the instruc-
tions
G. Causality and outcome Pharmacists often don’t know the patient’s outcome
Pharmacists would like to pass the form to another care 
provider for completion (e.g., GP)
Provide option for other care provider(s) to 
complete symptom resolution and outcome 
reporting.
Requires linkage to MD electronic data entry
H. Report submission Improve clarity of instructions for inpatient reporting
Pharmacists are hesitant to report without a definite 
diagnosis, especially if their identification is attached to 
the report
Simplify reporting options
Add option to remove or modify existing report(s)
Educate pharmacists that the form is primarily to 
improve documentation and communication 
between care providers, rather than to report
Change name of form to “documentation and 
communication” to clarify intent
I. Follow-up items Field is unnecessary Remove free-text boxes
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documentation, indicating the need for education and 
guidance around this during the implementation phase 
of the electronic fields. They were also hesitant to report 
events in which they had not witnessed the patient’s 
outcome, as the outcome often impacted their causality 
assessment. Finally, they were reluctant to report sus-
pected events. Most pharmacists initiated ADE docu-
mentation independently, without discussing the case 
with other care providers, even though an ADE diag-
nosis requires ruling out alternative diagnoses by the 
treating physician (e.g., ruling out of urinary tract infec-
tion prior to ascribing a diagnosis of delirium to a drug). 
Of completed forms, 15 of 22 (68  %) listed as outcome 
“requires follow-up,” highlighting the importance of ena-
bling communication by allowing multiple care providers 
to access an electronic ADE report in both the inpatient 
and outpatient settings. This could enable communica-
tion whenever follow-up is provided in a different health-
care setting (e.g., after hospital discharge). Pharmacists 
were concerned that incorrectly reported suspect ADEs 
could conceivably hinder a patient’s future access to indi-
cated medications. Thus, in an electronic design, report-
ers must be provided with the option of communicating 
with other care providers about new ADEs, as well as any 
changes to the patient status, as means of overcoming 
concerns about withholding what might be appropriate 
medications.
The average data field completion across all ADE forms 
was 50 % (95 % CI 47–53 %, n = 24). The least completed 
sections were D “are there symptoms, diagnoses, or labo-
ratory tests that you suspect are an ADE manifestation?” 
of which, on average, only 41 % (95 % CI 35–47 %, n = 24) 
were complete. The low completion rate within section D 
was primarily due to the pharmacist deciding that only 
one field was necessary to express the problem caused by 
the ADE—generally either “symptom” or “diagnosis” (e.g. 
a cough caused by Ramipril did not require diagnosis and 
lab data, “GI bleed” was sufficient to describe an ADE to 
Rivaroxaban). Section F “add new medication” was only 
completed 19 % (95 % CI 6–32 %) of the time. Five out of 
six pharmacists generally completed one of four data col-
lection fields in section D (symptoms, diagnosis, lab data, 
or additional comments), as not all fields were relevant 
to each ADE (e.g., lab values are only relevant when ADE 
has biochemically measurable outcomes). Pharmacists 
would usually fill out either the “symptom” or “diagnosis” 
of the ADE, but usually not both as this information was 
perceived as somewhat redundant. Our findings high-
light the fact that form certain ADEs the report can be 
complete, even though users may not fill out all the data 
fields.
The most commonly reported ADEs were catego-
rized as adverse drug reactions (16/24; 67 %) followed by 
drug–drug interactions (3/24; 13  %) and allergies (3/24; 
13  %). The most common choice of treatment was dis-
continuation of the drug (15/24; 63 %). Pharmacists were 
reluctant to report any information about symptom res-
olution, and most commonly selected: “patient requires 
follow-up” (15/22; 68 %), as they were often not privy to 
this information at the time of reporting because symp-
tom resolution would often occur only after discharge 
necessitating that another healthcare provider follow-up 
and complete the form. Follow-up was deemed neces-
sary to report on alternative diagnoses that could rule out 
an ADE, and to update incomplete information (e.g., lab 
results).
The average time required to complete one form was 
5.0 min (95 % CI 4.4–5.6 min, n = 12). The average num-
ber of internal interruptions was between 2 and 7, with 
a median number of 3 interruptions per form. Most 
interruptions occurred in order to access the printed 
patient’s outpatient medication dispensing record. Once 
implemented electronically, this step will be facilitated by 
prepopulating the ADE reporting form with a list of the 
patient’s dispensed medications, allowing pharmacists to 
tick the suspect drug(s) for the ADE.
Discussion
Our objective was to pilot-test a paper-based version of 
a newly designed ADE reporting form in three clinical 
settings prior to integrating it into an EMR. Our work 
highlights the utility of pilot-testing health technology 
interventions by intended end-users within clinical set-
tings in order to maximize user-friendliness, utility and 
relevance, even in  situations in which end-users were 
involved in earlier design stages. While there are dif-
ferences between electronic and paper data collection 
forms, the two approaches can produce synonymous 
results (Boyer et al. 2002; Huang 2006). Although not all 
functionalities of an electronic form can be mimicked by 
a paper-based form, crucial design elements required for 
a successful electronic implementation became apparent 
to end-users in paper-based testing and will influence our 
future electronic build. Our fieldwork helped end-users 
and researchers anticipate how the ADE form’s function-
ality could be improved to assist clinicians in communi-
cating relevant ADE information between care providers 
on different wards and across healthcare sectors, and as 
handover tools. This enabled us to anticipate the need 
for electronic linkages between different components of 
the EMR being implemented, ideally including a bidirec-
tional link with drug plan data.
One of our concerns at the outset was that the form 
would be too lengthy and require too much time to com-
plete, distracting its users from other work duties. Sur-
prisingly, our fieldwork did not confirm this, as most 
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users completed the form within 5  min and generally 
approved of its length and level of detail. Although the 
paper-based version did not allow us to display future 
functionalities (e.g., pop-up windows, ability to revise 
ADE reports in the future), end-users were able to iden-
tify preferences when different design options were pro-
posed. An important caveat is that additional features 
added in an electronic build may contribute to increased 
functionality, but may also add complexity and require 
more time, necessitating further refinements.
ADEs are vastly underreported using current ADE 
reporting systems (Hohl et  al. 2013; Wiktorowicz et  al. 
2010). Our fieldwork identified important avenues for 
improving reporting that may be addressed in a future 
electronic ADE documentation and communication form 
that is integrated into an EMR. These include address-
ing uncertainty about which ADE types should be docu-
mented (possibly through pop-up instructions), allowing 
providers to document uncertainty in the ADE diag-
nosis, enabling reports to be removed or modified after 
follow-up, providing space for alternative diagnoses, and 
enabling inter-professional communication across hand-
overs and between inpatient and outpatient settings (pos-
sibly via patient-specific safety alerts). In our study, the 
majority of reported ADEs were adverse drug reactions. 
Other kinds of ADEs, such as non-adherence, sub- or 
supra-therapeutic doses were seen as more complicated, 
as the implications of reporting were less clear. We used 
an extended definition of an ADE, which included non-
compliance and improper dosing regiments. While, all 
these events fall under the scope of medication-related 
problems (MRPs), our form purposely avoided this term 
to increase signal to noise ratio, and prevent reporting 
multiple non-clinically significant events per patient, as 
our overarching goal was to prevent recurrence of seri-
ous ADEs while avoiding alert fatigue and rendering 
documentation feasible. In previous workshops we held 
with end-users in advance of pilot-testing, pharmacists’ 
insisted on retaining the option to record non-adverse 
drug reaction ADEs (unpublished data). This conundrum 
might be addressed by educating users about the various 
kinds of ADEs encountered and need for communication 
across providers, and supporting a common approach to 
preventing future ADEs.
This study confirms previous observational work by 
our group that suggests that ADE diagnosis is a com-
plex and multi-step process (unpublished data). If ADE 
reporting is to succeed, electronic forms that are created 
for this process must reflect this complexity, and enable 
reporting as a multi-step process. Multiple care providers 
including those who provide insight into alternative diag-
noses for suspect events or provide follow-up of patient 
outcomes must be able to access and update information. 
The immediate implication for the design of electronic 
reporting systems is that they must enable communica-
tion between providers and across healthcare sectors. 
While we piloted the form with clinical pharmacists, 
doctors and nurses in hospital and community settings 
are likely to utilize the form as well. Thus, we anticipate 
further piloting and design adjustments as the form is 
implemented in other healthcare environments and for 
other provider groups.
During our fieldwork, we referred to the ADE form 
as a reporting tool. However “reporting” was very spe-
cifically associated with the communication of a subset 
of events to Health Canada through MedEffect form, as 
opposed to their documentation within an electronic 
record. An implication of “reporting” was an assumed 
permanency of the record that would be created, as 
none of the currently available reporting mechanisms 
allow for updates or modification after a report has 
been generated. As the overarching objective of our 
project is to develop a documentation tool that sup-
ports communication between care providers (rather 
than communicate events to external agencies), we 
changed the name of our form to “Adverse Drug Event 
Communication and Documentation Form” to high-
light its intended purpose. We hope that our findings 
highlight the need for a culture shift around ADE com-
munication, from an approach that serves to generate 
health data for external agencies, implied by “report-
ing”, to a patient-safety oriented approach that focuses 
on communication and documentation for prevention 
of repeat events.
Low completion rates can indicate problems with 
availability of information needed to complete a section 
of the form, or content problems with the section itself. 
Among the sections with the highest non-completion 
rates were those for the ADE symptom and diagnosis. 
ADEs are notoriously difficult to diagnose, and our prior 
observational work and workshops with stakeholders 
suggested that providing a record which allowed a subse-
quent care provider to re-trace evidence upon which an 
ADE diagnosis was based as an important aspect of ADE 
documentation. Pharmacists often listed presumed ADE 
symptoms; however clustering them into a diagnosis can 
be challenging, or require communication with physi-
cians to rule out alternative diagnoses or await the results 
of confirmatory testing, leading them to skip this field. 
This finding may also in part explain some of the uncer-
tainty expressed by pharmacists about reporting more 
complex, or less traditional ADEs.
Pharmacists were often unclear about which treat-
ment recommendations to list within the ADE doc-
umentation form (e.g., whether to document the 
medication used to treat the ADE, or a medication used 
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to replace the culprit drug). As a result users would 
often leave this field empty. We were unable to capture 
the full functionality of our electronic form—which 
will enable the pharmacist to recommend changes to a 
patient’s medication regiment using the EMR to a physi-
cian who can approve of them or alter them. While the 
electronic build may contain sufficient contextual infor-
mation to address the ambiguities which existed in the 
paper based version of the form, this is likely to require 
electronic piloting.
Our findings demonstrate the value of completing 
pilot studies of electronic health information technology 
implementations with paper-based forms. While these 
cannot mimic the full functionality of an electronic inter-
face, they provided vital feedback for subsequent design 
and pre-implementation user education that we might 
have otherwise overlooked, including questions regard-
ing systems architecture.
Limitations
Lightweight ethnography, although time and resource 
efficient, carries a risk of only skimming the surface and 
providing only partial explanations. By only briefly engag-
ing in the work environment, the observers risk missing 
less common routines and events that could otherwise 
have been captured. We relied on volunteers as the sub-
jects of our observations, and therefore used a limited 
number of participants. This study is limited by the sole 
inclusion of clinical pharmacists, who were identified in 
our healthcare settings as the most likely care providers 
to encounter and document ADEs. It is possible that we 
might have uncovered other aspects of the ADE form 
requiring modifications had we been able to recruit more 
participants from other clinical backgrounds or settings, 
and anticipate further design adjustments as the use of 
the form is expanded. Also, our findings are susceptible 
to the Hawthorne effect, which occurs when participants 
are aware of the study objectives, potentially influencing 
their behavior. Finally, paper-based field evaluation of 
software designs has limitations, and hence findings must 
be evaluated in relation to data collected through other 
means.
Conclusion
We piloted a paper-based version of an ADE documen-
tation form prior to its electronic build. As a result, we 
were able to modify its design, and envision unique 
requirements for the system’s architecture as well as 
educational needs prior to system implementation. As a 
result of our pilot study, we will be able to address these 
issues to enhance functionality prior to an electronic 
build.
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